학술논문

Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy
Document Type
article
Source
JCI Insight. 5(4)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
HIV/AIDS
Infectious Diseases
Substance Misuse
Sexually Transmitted Infections
Drug Abuse (NIDA only)
Cancer
Infection
Adult
Anti-HIV Agents
CD4 Lymphocyte Count
CD4-CD8 Ratio
CD4-Positive T-Lymphocytes
Cohort Studies
DNA
Viral
Disease Reservoirs
Female
HIV Infections
HIV-1
Humans
Male
Middle Aged
Polymerase Chain Reaction
Proviruses
Virus Latency
AIDS/HIV
Molecular biology
Biomedical and clinical sciences
Health sciences
Language
Abstract
BACKGROUNDThe relative stabilities of the intact and defective HIV genomes over time during effective antiretroviral therapy (ART) have not been fully characterized.METHODSWe used the intact proviral DNA assay (IPDA) to estimate the rate of change of intact and defective proviruses in HIV-infected adults on ART. We used linear spline models with a knot at seven years and a random intercept and slope up to the knot. We estimated the influence of covariates on rates of change.RESULTSWe studied 81 individuals for a median of 7.3 (IQR 5.9-9.6) years. Intact genomes declined more rapidly from initial suppression through seven years (15.7% per year decline; 95% CI -22.8%, -8.0%) and more slowly after seven years (3.6% per year; 95% CI -8.1%, +1.1%). The estimated half-life of the reservoir was 4.0 years (95% CI 2.7-8.3) until year seven and 18.7 years (95% CI 8.2-infinite) thereafter. There was substantial variability between individuals in the rate of decline until year seven. Intact provirus declined more rapidly than defective provirus (P < 0.001) and showed a faster decline in individuals with higher CD4+ T cell nadirs.CONCLUSIONThe biology of the replication-competent (intact) reservoir differs from that of the replication-incompetent (non-intact) pool of proviruses. The IPDA will likely be informative when investigating the impact of interventions targeting the reservoir.FUNDINGDelaney AIDS Research Enterprise, UCSF/Gladstone Institute of Virology & Immunology CFAR, CFAR Network of Integrated Systems, amfAR Institute for HIV Cure Research, I4C and Beat-HIV Collaboratories, Howard Hughes Medical Institute, Gilead Sciences, Bill and Melinda Gates Foundation.